13 stories mentioning HKG:3692Updated just now
Every FINWIRES story that references HKG:3692, newest first.
Recent broker actions mentioned in FINWIRES coverage. Compiled from wire headlines; not investment advice.
Hansoh Pharmaceutical (HKG:3692) said its self-developed HS-10374 met the co-primary endpoints in a Phase 3 trial for adults with moderate-to-severe plaque psoriasis, according to a Monday filing with the Hong Kong bourse.The drug showed a favorable safety and tolerability profile, with no new safety signals observed.Hansoh plans to begin discussions with Chinese regulators to prepare a new drug application.
Hansoh Pharmaceutical Group (HKG:3692) said its self-developed HS-20197 injection has received clinical trial approval from China's National Medical Products Administration.The Class 1 innovative drug is being developed for advanced solid tumors, according to a Wednesday Hong Kong exchange filing.
Hansoh Pharmaceutical's (HKG:3692) risvutatug rezetecan for injection was included in the priority review and approval procedure of China's National Medical Products Administration.The move followed positive results from a phase 3 trial of the drug for small cell lung cancer, according to a Friday bourse disclosure.
Hansoh Pharmaceutical's (HKG:3692) biologics license application for HS-20093 for injection was accepted by China's National Medical Products Administration.The drug is for the treatment of adult patients with small cell lung cancer, according to a Wednesday Hong Kong bourse filing.
Hansoh Pharmaceutical (HKG:3692) will lower the conversion price of its HK$4.68 billion zero-coupon convertible bonds due 2033 to HK$56.54 per share from HK$57.39, effective Sept. 28, according to a Wednesday Hong Kong bourse filing.The adjustment follows the payment of the interim dividend for the six months ended June 30.All other terms of the bonds remain unchanged, the filing said.
Hansoh Pharmaceutical Group (HKG:3692) reported 4.26 billion yuan in profit attributable to owners for the first half, compared with 3.13 billion yuan a year ago, a Wednesday bourse filing showed.EPS moved to 0.70 yuan from 0.53 yuan year over year.For the six months ended June 30, revenue was 8.3 billion yuan, versus 7.43 billion yuan previously, the pharmaceutical company said.The company declared an interim dividend of HK$0.285 per share for the period, payable Oct. 29 to shareholders of record as of Sept. 25.
Hansoh Pharmaceutical Group Company (HKG:3692) proprietary antibody-drug conjugate HS-20093 met the primary endpoint in a Phase 3 trial in patients with relapsed or refractory osteosarcoma.The drug demonstrated a statistically significant improvement in progression-free survival versus chemotherapy, with benefits also seen in overall survival and investigator-assessed progression-free survival, according to a Tuesday Hong Kong bourse filing. The company plans to begin discussions with Chinese regulators to prepare a biologics license application following the positive results.
Hansoh Pharmaceutical Group (HKG:3692) has an average rating of buy and mean price target of HK$44.55, according to analysts polled by FactSet.
Hansoh Pharmaceutical's (HKG:3692) obtained two clinical trial approvals for HS-20136-2 injection from China's National Medical Products Administration.The drug will be tested for the indications of type 2 diabetes mellitus and weight management.
Hansoh Pharmaceutical's (HKG:3692) new drug application for HS-10568 Injection was accepted by China's National Medical Products Administration, according to a Wednesday Hong Kong bourse filing.The acceptance is for use of the drug secondary hyperparathyroidism in adult patients with chronic kidney disease undergoing hemodialysis.
Hansoh Pharmaceutical (HKG:3692) said China's National Medical Products Administration accepted its application of olatorepatide injection to treat obesity, according to a Thursday filing with the Hong Kong bourse.The drug is meant to be administered once a week.Shares of the company fell nearly 1% in recent morning trade.
Hansoh Pharmaceutical's (HKG:3692) obtained clinical trial approval for its HS-10541 tablets from China's National Medical Products Administration, according to a Wednesday Hong Kong bourse filing.Shares of the pharma firm were down over 1% in Thursday afternoon trading.The trial will study the drug for the treatment of patients with KRAS G12C-mutated advanced solid tumors.
Hansoh Pharmaceutical's (HKG:3692) HS-20093 for injection in combination with adebrelimab obtained approval to be included as a Breakthrough Therapy Designated Drug from China's National Medical Products Administration, according to a Thursday Hong Kong bourse filing.The approval is for the indication of locally advanced or metastatic non-small cell lung cancer.
